Sign In
Buy BBLG
$1.26
-0.0080 (-0.630%)
At Close: Jun 03, 2026
Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook
08:00am, Thursday, 08'th Jan 2026
Key accomplishments include expanded rhNELL-1 shelf life, advanced NB1 development, strengthened balance sheet, and maintained Nasdaq compliance Key accomplishments include expanded rhNELL-1 shelf lif
Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months
08:00am, Tuesday, 23'rd Dec 2025
Milestone advances manufacturing readiness and supports long-term commercialization strategy Milestone advances manufacturing readiness and supports long-term commercialization strategy
Bone Biologics (NASDAQ:BBLG) Shares Down 0.5% – Should You Sell?
02:26am, Thursday, 11'th Dec 2025
Bone Biologics Corp. (NASDAQ: BBLG - Get Free Report)'s share price fell 0.5% during trading on Wednesday. The stock traded as low as $1.9246 and last traded at $2.10. 43,801 shares were traded during
Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook
07:00am, Thursday, 04'th Sep 2025
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announ
Bone Biologics Announces Closing of $5.0 Million Public Offering
04:10pm, Monday, 30'th Jun 2025
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today
Why Is Bone Biologics Stock Surging On Friday?
10:23am, Friday, 27'th Jun 2025
Bone Biologics Corporation BBLG stock is trading higher on Friday, with a session volume of 17.22 million compared to the average volume of 38.795K as per data from Benzinga Pro.
Bone Biologics Announces Pricing of $5.0 Million Public Offering
09:10am, Friday, 27'th Jun 2025
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today
Bone Biologics Files Patent Application for Bone Regeneration Technology
07:00am, Friday, 27'th Jun 2025
BURLINGTON, Mass.--(BUSINESS WIRE)---- $BBLG #Bonebiologics--Bone Biologics files U.S. patent application for bone regeneration technology.
Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements
04:20pm, Thursday, 26'th Jun 2025
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today
Bone Biologics Announces 1-for-6 Reverse Stock Split
08:00am, Friday, 06'th Jun 2025
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today
Bone Biologics Announces Exercise of Warrants for $2.1 Million Gross Proceeds
08:00am, Friday, 02'nd Aug 2024
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today
First Two Patients Treated in Pilot Clinical Study with Bone Biologics' NB1 Bone Graft Device in Spine Fusion
08:00am, Thursday, 20'th Jun 2024
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announ
Bone Biologics Announces Closing of $2.0 Million Public Offering
04:15pm, Wednesday, 06'th Mar 2024
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today
Bone Biologics Announces Pricing of $2.0 Million Public Offering
09:15am, Monday, 04'th Mar 2024
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today
Bone Biologics Reports Progress With NB1 Clinical Program
08:00am, Friday, 01'st Mar 2024
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, reports progress with advancing its product candidate NB1
